Main Menu

Month: June 2021

HistoIndex’s AI-Based Digital Pathology Indicates Concomitant Histological Improvements in Liver Fat and Fibrosis in Nonalcoholic Steatohepatitis (NASH) Patients Treated with Tropifexor Compared with Placebo

Press Release / By

HistoIndex’s AI-Based Digital Pathology Indicates Concomitant Histological Improvements in Liver Fat and Fibrosis in Nonalcoholic Steatohepatitis (NASH) Patients Treated with Tropifexor Compared with Placebo   SINGAPORE, June 25, 2021 – HistoIndex’s Second Harmonic Generation (SHG) stain-free digital pathology platform has shown marked reduction in liver fibrosis (overall, reduction in perisinusoidal fibrosis, as well as regression of …

HistoIndex’s AI-Based Digital Pathology Indicates Concomitant Histological Improvements in Liver Fat and Fibrosis in Nonalcoholic Steatohepatitis (NASH) Patients Treated with Tropifexor Compared with Placebo Read More »

Singapore: A Myriad of Biotech Financing Strategies

Media Coverage / By

Precision diagnostics firm Histoindex began life as a spinoff from A*STAR and so received funding from the Singaporean government as well as from angel investors, corporations, and institutions. Co-founder and CEO, Dr. Gideon Ho, highlights Singapore’s advantages for innovative start-up firms looking to grow in Singapore.

Connect with us

Linkedin Youtube

Pages

Locations

Singapore HQ
Teletech Park
20 Science Park Road, #01-26/27
Singapore 117674

UK Branch
Queen Elizabeth University Hospital,
Imaging Centre of Excellence, L3-18, Langlands Drive, Glasgow G51 4LB,
United Kingdom

China Subsidiary Office
Room 1001, Building 10
No. 188 Binkang Road, Hangzhou
Zhejiang 310051, China

©2024 Histoindex Pte Ltd. All Rights Reserved. All logos and trademarks are the property of HistoIndex or their respective owners.